POPULARITY
Categories
57 episodes with Targeted therapy
35 episodes with Targeted therapy
43 episodes with Targeted therapy
43 episodes with Targeted therapy
39 episodes with Targeted therapy
39 episodes with Targeted therapy
57 episodes with Targeted therapy
31 episodes with Targeted therapy
41 episodes with Targeted therapy
31 episodes with Targeted therapy
37 episodes with Targeted therapy
14 episodes with Targeted therapy
13 episodes with Targeted therapy
38 episodes with Targeted therapy
13 episodes with Targeted therapy
9 episodes with Targeted therapy
13 episodes with Targeted therapy
9 episodes with Targeted therapy
13 episodes with Targeted therapy
7 episodes with Targeted therapy
6 episodes with Targeted therapy
11 episodes with Targeted therapy
6 episodes with Targeted therapy
10 episodes with Targeted therapy
4 episodes with Targeted therapy
7 episodes with Targeted therapy
3 episodes with Targeted therapy
3 episodes with Targeted therapy
3 episodes with Targeted therapy
4 episodes with Targeted therapy
10 episodes with Targeted therapy
3 episodes with Targeted therapy
4 episodes with Targeted therapy
10 episodes with Targeted therapy
2 episodes with Targeted therapy
4 episodes with Targeted therapy
In this episode of the Oncology Brothers podcast, Drs. Rahul & Rohit Gosain wrap up their three-part CME series on HER2-positive biliary tract cancer. Joined by Dr. Rachna Shroff, they delved into the critical topic of managing adverse events associated with treatments like TDXD and Zanidatamab. The discussion covered: • Overview of the treatment landscape for biliary tract cancer • Common side effects of TDXD, including interstitial lung disease, nausea, and fatigue • Management strategies for adverse events, including dose reductions and supportive care • Insights on Zanidatamab, its side effects, and infusion-related reactions • The importance of biomarker testing and patient-centered care in treatment decisions Tune in to gain valuable insights on how to improve patient quality of life while navigating the complexities of HER2-positive biliary tract cancer treatments. Follow us on social media: • X/Twitter: https://twitter.com/oncbrothers • Instagram: https://www.instagram.com/oncbrothers • Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!
In this episode of Hema Now, Diu Nguyen joins Jonathan Sackier to discuss breakthroughs in acute myeloid leukaemia (AML) research. From RNA-binding proteins to the future of stem cell-targeted therapies, Nguyen shares the translational goals of her lab and what's on the horizon in AML diagnosis and treatment. Timestamps: 01:20 – Quickfire Insights 03:32 – AML Breakthroughs 04:47 – Leukaemia Surprise 06:42 – Alternate Pathways 07:54 – RNA Differences 12:08 – Diagnostics Future 14:03 – RBMX Spotlight 20:21 – Targeted Therapies 27:07 – Treatment Barriers 31:32 – Three Wishes
This episode features the Beamion LUNG-1 trial, where zongertinib showed a 71% response rate in previously treated HER2-mutant NSCLC patients. The EAGLE-1 trial found gepotidacin non-inferior to standard treatment for urogenital gonorrhoea, with a 92.6% success rate. The U.S. Department of Health and Human Services and NIH launched the Generation Gold Standard initiative, a universal vaccine platform targeting pandemic-prone viruses, with trials ongoing for H5N1 avian influenza and coronaviruses.
Welcome to the Oncology Brothers podcast! In this episode, Drs. Rohit and Rahul Gosain are joined by Dr. Ghassan Abou-Alfa, a medical oncologist specializing in the hepatobiliary space at Memorial Sloan Kettering. Together, they explored the current treatment landscape of biliary tract cancer, focusing on the advancements in HER2-driven therapies. Key topics discussed included: • The evolution of treatment options for biliary tract cancer, including chemotherapy and immunotherapy. • The significance of genetic testing, including IDH1 mutations, FGFR alterations, and HER2 status. • The role of multidisciplinary collaboration in managing hepatobiliary cancers. • Insights into the latest clinical trials and emerging therapies for HER2-positive biliary tract cancer. Join us as we delve into the complexities of biliary tract cancer and the promising developments in HER2-targeted treatments. Don't forget to check out our next episode, where we will take a deeper dive into the data surrounding HER2 therapies and discuss management strategies for common side effects. YouTube: https://youtu.be/pGiU7JJGNOc Follow us on social media: • X/Twitter: https://twitter.com/oncbrothers • Instagram: https://www.instagram.com/oncbrothers • Website: https://oncbrothers.com/ Subscribe to stay updated on the latest in oncology! #OncologyBrothers #BiliaryTractCancer #HER2 #CancerTreatment #MedicalOncology #CME #Podcast
In this episode of Hema Now, Jonathan Sackier is joined by John Riches, Clinical Reader in Cancer Immunometabolism at the Barts Cancer Institute and Honorary Consultant Haemato-oncologist. They explore how metabolic shifts drive lymphoma progression, the potential of immunotherapy, and what the future holds for treating lymphoid malignancies. Timestamps: 00:00 – Introduction 01:46 – Riches' journey into haematology 03:42 – What is T cell exhaustion? 07:06 – The key role of metabolism in lymphoma 09:33 - Richter's syndrome 13:17 – Breakthroughs in immunotherapy 20:27 – The challenges of translational research 25:39 – B cells in autoimmune diseases 28:16 – The potential of breath biopsy 32:58 – Riches' three wishes for healthcare
In this episode, hear Lauren Byers, MD and Christine Hann, MD share their insights on the latest data regarding new therapies targeting B7-H3 in small cell lung cancer including: Rationale for targeting B7-H3Overview of the structure of antibody-drug conjugates (ADCs)Results from the phase I/II IDeate-PanTumor01 trial of ifinatamab deruxtecan (I-DXd) in ES-SCLCData from the phase II IDeate-Lung02 trial of 2 different doses of I-DXd in patients with previously treated ES-SCLCAn overview of the ongoing phase III trials IDeate-Lung02 and IDeate-Lung03 of I-DXd in SCLCEarly phase evidence on other novel B7-H3 ADCs including YL201 and HS-20093Program faculty:Lauren Byers, MDProfessor and Thoracic Section ChiefDepartment of Thoracic/Head and Neck Medical OncologyMD Anderson Cancer CenterHouston, TexasChristine L. Hann, MD, PhDAssociate Professor of OncologyDirector, Small Cell Lung Cancer TherapeuticsJohns Hopkins University School of MedicineBaltimore, Maryland
Jo Cheah talks to Bronwyn Jenkins, consultant neurologist, about the role of calcitonin gene-related peptide (CGRP)–targeted therapies in migraine treatment. Bronwyn explains the difference between tension-type headaches and migraines, and outlines current treatment options. The conversation also covers adverse effects, patient eligibility, and other important considerations for prescribers. Read the full article in Australian Prescriber.
ReferencesSignal Transduction and Targeted Therapy 2019. volume 4, Article number: 7 JAMA. 2024 Dec 10;332(22):1924–1935. ACS Nano , 2025.January 27.Vol 19/Issue 5Guerra, DJ. 2025. Unpublished Lectures.Clapton &Whitlock. 1970."Why does Love have to be so Bad?" on LAYLA lp.https://open.spotify.com/track/6S5DtyJNXTgHEXIVUToAPP?si=e2c45a57168f4f6eAllman, D 1970 "Little Martha" on EAT A PEACH lp.https://open.spotify.com/track/2WPLFvAldG0GG6Ad3Xa0TO?si=8d5e8ed3fa934860Mozart, WA. 1791 "Clarinet Concerto in A Major. K.622https://open.spotify.com/album/5PerO11RxVNvixJPjW4UAl?si=2Jnw72E6QueNO6I9ff6Wzw
00:00 Introduction and Overview of Caristo Diagnostics09:08 The Technology Behind Carry Heart18:00 Clinical Implications and Risk Assessment27:27 Actionable Steps for Patients30:34 Optimizing Cardiovascular Drug Dosing32:31 AI in Cardiovascular Medicine33:50 Leveraging Historical Data for Risk Prediction36:25 AI's Role in Molecular Pathway Analysis39:03 GLP-1 and Cardiovascular Outcomes41:56 Targeted Therapies in Cardiovascular Treatment42:45 Building Trust in New Technologies49:16 Regulatory Approvals and Future Prospects54:15 Expanding Applications Beyond Cardiology57:16 Looking Ahead: The Future of Caristo Diagnostics
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PZK865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until March 26, 2026.ALK+ mNSCLC Care Compass: Taking Your Best Shot First—Selecting and Sequencing Targeted Therapy and Teaming Up to Achieve Long-Term Success In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Pfizer.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PZK865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until March 26, 2026.ALK+ mNSCLC Care Compass: Taking Your Best Shot First—Selecting and Sequencing Targeted Therapy and Teaming Up to Achieve Long-Term Success In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Pfizer.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PZK865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until March 26, 2026.ALK+ mNSCLC Care Compass: Taking Your Best Shot First—Selecting and Sequencing Targeted Therapy and Teaming Up to Achieve Long-Term Success In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Pfizer.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PZK865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until March 26, 2026.ALK+ mNSCLC Care Compass: Taking Your Best Shot First—Selecting and Sequencing Targeted Therapy and Teaming Up to Achieve Long-Term Success In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Pfizer.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PZK865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until March 26, 2026.ALK+ mNSCLC Care Compass: Taking Your Best Shot First—Selecting and Sequencing Targeted Therapy and Teaming Up to Achieve Long-Term Success In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Pfizer.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PZK865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until March 26, 2026.ALK+ mNSCLC Care Compass: Taking Your Best Shot First—Selecting and Sequencing Targeted Therapy and Teaming Up to Achieve Long-Term Success In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Pfizer.Disclosure information is available at the beginning of the video presentation.
Drs. Sabari and Yu discuss the molecular landscape of HER2-mutant lung cancer, including its genomic characteristics, common co-mutations, and differences between HER2 mutations and HER2 amplification. This discussion also explores the prevalence and clinical patterns of HER2 mutations, their oncogenic mechanisms, their impact on tumor behavior and metastases, and potential environmental or genetic contributors to their development.
CME credits: 1.00 Valid until: 21-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/CaseConsultAdverseEffectMonitoringManagementandMitigationDuringTargetedTherapyforBRAFMutantmCRc/33134/ In this series, Dr. Fortunato Ciardiello and Dr. Jenny Seligmann review the management of metastatic colorectal cancer (mCRC), with a focus on timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, the management of treatment-related adverse events.
The standard approach of “7 + 3” chemotherapy in acute myeloid leukemia (AML) treatment has been in place for 50 years. But that may soon change, says Maximilian Stahl, MD, a member of the Adult Leukemia Group at the Dana-Farber Cancer Institute in Boston and a member of the faculty at Harvard University. “My prediction is that in 10 years, you will not see much 7 + 3 anymore. Maybe not even 10 years, maybe five years,” he tells Robert A. Figlin, MD, the interim director and Steven Spielberg Family Chair in Hematology-Oncology at the Cedars-Sinai Cancer Center in Los Angeles. Dr. Stahl describes how targeted therapies such as menin inhibitor revumenib (Revuforj), which was recently approved by the U.S. Food and Drug Administration, are transforming AML care. Although currently indicated for relapsed/refractory disease, trials are exploring frontline use. “Pretty much, if you can think of any combination treatment in your head, that is already an ongoing clinical trial,” Dr. Stahl explains. He outlines how targeted therapies have already changed practice and looks to what advances are likely in the near future. Dr. Stahl reported a consulting or advisory role with the Boston Consulting Group, Clinical Care Options, Curis Oncology, GlaxoSmithKline, Haymarket, Kymera, Novartis, and Sierra Oncology. Dr. Figlin reported various financial relationships.
Interview with Timothy M. Pawlik, MD, PhD, MPH, MTS, MBA, author of Molecular Testing and Targeted Therapies in Hepatobiliary Cancers: A Review. Hosted by Amalia Cochran, MD. Related Content: Molecular Testing and Targeted Therapies in Hepatobiliary Cancers
Interview with Timothy M. Pawlik, MD, PhD, MPH, MTS, MBA, author of Molecular Testing and Targeted Therapies in Hepatobiliary Cancers: A Review. Hosted by Amalia Cochran, MD. Related Content: Molecular Testing and Targeted Therapies in Hepatobiliary Cancers
Dermatologic toxicities associated with oncology treatment can significantly impact quality of life and treatment adherence for patients with breast cancer. The Association of Cancer Care Centers (ACCC) is committed to providing up-to-date guidance on managing these dermatologic side effects to enhance clinical outcomes. In this episode of CANCER BUZZ, Allison Gordon, MD, a supportive oncodermatologist at Memorial Sloan Kettering Cancer Center, discusses the dermatologic toxicities associated with breast cancer treatment. Dr Gordon explores preventive measures that oncologists can implement early in the treatment course and offers alternative resources for oncology clinicians when an oncodermatologist referral is not feasible. Additionally, she highlights capivasertib, a recently approved antineoplastic drug, and reviews its associated cutaneous adverse events, along with supportive care and management strategies. Thank you to AstraZeneca for their support of this program. Allison Gordon, MD Dermatologist Memorial Sloan Kettering Cancer Center New York, NY “Because many of these medications can cause dry skin, which can be debilitating for patients... [we recommend] using a thick ointment or cream moisturizer on their damp skin after they shower... it doesn't have to be anything expensive... I always recommend that to all patients regardless of what treatment they're on.”– Allison Gordon, MD Additional Reading/Sources ACCC Supportive Care Strategies for Dermatologic Toxicities Related to Cancer Therapies education program (https://www.accc-cancer.org/home/learn/comprehensive-cancer-care-services/dermatologic-toxicities?) Targeted Therapy Side Effects – American Cancer Society (https://www.cancer.org/cancer/managing-cancer/treatment-types/targeted-therapy/side-effects.html) Oncodermatology: Advancing the Science and Care of Cancer Patients and Survivors (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10569770/) Dermatologic Adverse Events of Systemic Anticancer Therapies: Cytotoxic Chemotherapy, Targeted Therapy, and Immunotherapy (https://ascopubs.org/doi/10.1200/EDBK_289911) Multinational Association of Supportive Care in Cancer (MASCC) Oncodermatolgy Study Group (https://mascc.org/resources/mascc-guidelines/) Guidelines for the Prevention and Treatment of Radiation-Induced Skin Reactions (https://mascc.org/resources/mascc-guidelines/) Guidelines for Prevention and Management of Dermatological Toxicities Related to Anticancer Agents (https://pubmed.ncbi.nlm.nih.gov/33248228/)
What if a cancer treatment worked—until it suddenly didn't? A new case report, “Acquired RUFY1-RET rearrangement as a mechanism of resistance to lorlatinib in a patient with CD74-ROS1 rearranged non-small cell lung cancer: A case report,” published in Oncotarget, reveals how a non-small cell lung cancer (NSCLC) patient developed drug resistance through a rare genetic alteration, allowing the cancer to evade therapy. This unexpected finding highlights the importance of advanced genetic testing and personalized cancer treatments. Non-Small Cell Lung Cancer, Targeted Therapy and Drug Resistance Non-Small Cell Lung Cancer is the most common type of lung cancer, accounting for nearly 85% of all cases. Some patients with NSCLC have genetic mutations, such as ROS1 gene fusions, that drive tumor growth. These patients often respond well to targeted therapies like lorlatinib, a ROS1 inhibitor that blocks cancer growth. However, cancer is constantly evolving. Over time, it can develop resistance to targeted therapies, leading to treatment failure. Understanding these resistance mechanisms is crucial for precision oncology, the approach of tailoring cancer treatment based on a patient's unique genetic profile. Full. blog - https://www.oncotarget.org/2025/03/12/a-rare-genetic-shift-that-helped-lung-cancer-evade-treatment/ DOI - https://doi.org/10.18632/oncotarget.28682 Correspondence to - Wade T. Iams - wade.t.iams@vumc.org Video short - https://www.youtube.com/watch?v=HE_qSkcRZho About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science). To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM
In this episode of the Onc Now Podcast, host Jonathan Sackier is joined by Heather McArthur, Associate Professor in the Department of Medicine at University of Texas, UT Southwestern Medical Center, USA. They discuss recent advancements in breast cancer immunotherapy and the future of personalised care. Timestamps: 00:00 - Introduction 01:20 - Transformative breakthroughs in immunotherapy 03:51 - Communicating new research to the public 05:48 - Racial disparities in cancer screenings 07:22 - Unmet needs in treating triple-negative breast cancer 11:48 - Genomic profiling and molecular pathways 13:30 - Barriers to personalised treatment plans 15:09 - Designing and conducting large-scale, international trials 19:16 - Optoacoustic imaging in cancer 22:52 - The ‘first' cell and the heterogeneity of breast tumours 25:21 – Heather's three wishes for healthcare
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/KRC865. CME credit will be available until February 26, 2026.Modern Practice Principles in Lung Cancer—First Find the Targets, Then Treat With Precision: A Concise Guide for Biomarker Testing and EGFR-Targeted Therapy in NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. Both are Johnson & Johnson companies.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/KRC865. CME credit will be available until February 26, 2026.Modern Practice Principles in Lung Cancer—First Find the Targets, Then Treat With Precision: A Concise Guide for Biomarker Testing and EGFR-Targeted Therapy in NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. Both are Johnson & Johnson companies.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/KRC865. CME credit will be available until February 26, 2026.Modern Practice Principles in Lung Cancer—First Find the Targets, Then Treat With Precision: A Concise Guide for Biomarker Testing and EGFR-Targeted Therapy in NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. Both are Johnson & Johnson companies.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/KRC865. CME credit will be available until February 26, 2026.Modern Practice Principles in Lung Cancer—First Find the Targets, Then Treat With Precision: A Concise Guide for Biomarker Testing and EGFR-Targeted Therapy in NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. Both are Johnson & Johnson companies.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/KRC865. CME credit will be available until February 26, 2026.Modern Practice Principles in Lung Cancer—First Find the Targets, Then Treat With Precision: A Concise Guide for Biomarker Testing and EGFR-Targeted Therapy in NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. Both are Johnson & Johnson companies.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/KRC865. CME credit will be available until February 26, 2026.Modern Practice Principles in Lung Cancer—First Find the Targets, Then Treat With Precision: A Concise Guide for Biomarker Testing and EGFR-Targeted Therapy in NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. Both are Johnson & Johnson companies.Disclosure information is available at the beginning of the video presentation.
Live from TTLC25: Targeted Therapy in Early Stage NSCLC Debate by IASLC
In this podcast, expert clinicians will discuss the latest clinical data on targeted therapies for management of patients with gMG. To claim CE credit after listening to this episode, go to this link and check the "Already listened on another platform?" box: https://healio.com/cme/mededtalks/neurology/20250220/3-exploring-the-latest-data-on-targeted-therapies-for-treating-gmg
This week, Jonathan is joined by Eytan Stein, Chief of the Leukaemia Service and an Attending Physician at Memorial Sloan Kettering Cancer Center, New York, USA. Timestamps: (00:00)-Introduction (01:05)-The current landscape of treatments (02:26)-The promise and peril of differentiation therapy (05:55)-Highlighting the most impactful clinical trials (08:38)-Epigenetics and the future of targeted therapies (10:40)-The BEAT AML master clinical trial (12:57)-The latest research into IDH inhibitors (16:10)-Therapies for splicing factor mutations (19:29)-Reducing patient fear with education (22:46)-Stein's three wishes for healthcare
In this episode of Lung Cancer Considered, host Dr. Narjust Florez leads a discussion on how small cell lung cancer continues to evolve with new treatment options and recent FDA approval. Listen to the episode to learn about the current standard of care and future therapies with a brief discussion about small cell transformation. Guest: Triparna Sen, MD Associate Professor Director, Lung Cancer PDX Program, Icahn School of Medicine at Mount Sinai Guest: Jacob Sands, MD Assistant Professor of Medicine, Harvard Medical School Lowe Cancer Center for Thoracic Oncology Dana Farber Cancer Institute
In this JCO Precision Oncology Article Insights episode, Jiasen He summarizes “Midline Low-Grade Gliomas of Early Childhood: Focus on Targeted Therapies.” by Dr. Ludmila Papusha et al. published on July 08, 2024. TRANSCRIPT Jiasen He: Hello and welcome to JCO Precision Oncology Article Insights. I'm your host Jiasen He, a JCO Journal's Editorial Fellow. Today, I will provide a summary on “Midline Low-Grade Gliomas of Early Childhood: Focus on Targeted Therapies.” This is an observational study by Dr. Ludmila Papusha and colleagues that investigated the use of target therapies in early childhood with midline low grade glioma. Low grade glioma located in the hypothalamic chiasmatic region, thalamus and the brain stem are classified as midline low grade gliomas. Due to their unique locations, complete surgical resection is usually not able to be achieved. In young children with low grade glioma, radiation therapy is generally not favored. Traditionally, chemotherapy regimens such as carboplatin and vincristine have been used. However, as Dr. Papusha noted, this population often exhibits poor response to chemotherapy. With a growing understanding of the RAS-RAF-MEK pathways in low grade glioma, targeted therapy has emerged as a promising treatment option for this group. However, limited data is available regarding the mutation status of midline low grade glioma in early childhood and real world evidence on their response to targeted therapy remains scarce. Dr. Papusha's research aimed to address this critical gap by evaluating the effectiveness of targeted therapy in midline gliomas of early childhood. In this observational study, 40 patients under the age of three with midline low grade glioma were enrolled. Somatic genetic aberrations associated with activation of RAS-RAF signaling pathway were identified in 95% of the cohort with BRAF fusion being the most common aberration followed by the BRAF V600E mutation. These findings confirm the presence of targetable mutations in this specific population and provide a foundation for the use of targeted therapy. Diencephalic syndrome is a rare neurologic disorder typically affecting infants and young children with tumors located in the diencephalon. In this cohort, 43% of the optic pathway and hypothalamic gliomas manifested diencephalic syndrome. Among 30 patients who received first line chemotherapy, primary carboplatin and vincristine, the two-year and five-year progression-free survival rate were only 24% and 6.4% respectively, indicating that most patients experience disease progression with chemotherapy. Targeted therapy was administered to 27 patients of whom 22 experienced disease progression during or after chemotherapy. A total of 26 patients were available for evaluation. Dr. Papusha reported that all patients benefited from targeted therapy with 12 achieving a partial response, 2 showing a minor response and 12 maintaining stable disease. The median duration of targeted therapy was 16 months. These findings demonstrate the efficacy of targeted therapy in this population. Regarding toxicity from targeted therapy in this population, the most common adverse event was grade 1 to 2 skin toxicity observed in 52% of patients. Severe toxicity occurred in 36% of patients treated with trametinib including grade 3 skin toxicity, mucositis and hematuria. Additionally, grade 3 gastrointestinal toxicity was reported. Interestingly, all three patients who experienced grade 3 gastrointestinal toxicity had diencephalic syndrome at the time of targeted therapy initiation. The author also noted cases of disease progression during treatment breaks. However, tumor response was restored in all affected patients upon resumption of targeted therapy. The two-year progression-free survival rate was 59%. In conclusion, Dr. Papusha states the unique characteristics of infantile midline low grade glioma, including the high prevalence of diencephalic syndrome and resistance to chemotherapy. The study contributes valuable information on the targetable mutation profile in this population and provides further evidence supporting the use of targeted therapy while emphasizing the need for low monitoring of severe adverse events. As the author notes, important questions remain regarding the long term side effects of kinase inhibitors in infants and children as well as optimal duration of therapy. Thank you for listening to JCO Precision Oncology Article Insights and please tune in for the next topic. Don't forget to give us a rating or review and be sure to subscribe so you never miss an episode. You can find all ASCO shows at asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement.
Featuring slide presentations and related discussion from Dr Joyce O'Shaughnessy, Dr Mark Pegram and Prof Peter Schmid, including the following topics: Strategies to Identify Patients with HER2-Low and HER2-Ultralow Breast Cancer (0:00) Case: A woman in her mid 50s initially presenting with ER-positive, HER2 IHC 1+ locally advanced breast cancer who experiences progression to HER2 0 metastatic disease (20:53) Case: A woman in her early 60s with ER-positive, HER2 IHC 1+ metastatic breast cancer (mBC) who experiences disease progression 8 months after starting first-line CDK4/6 and aromatase inhibitor (29:14) Expanding the Spectrum of Targeted Therapy (38:52) Case: A woman in her early 60s with HR-positive, HER2 IHC 1+ mBC who receives fifth-line T-DXd resulting in stable disease (1:04:13) Case: A woman in her early 50s with progressive HR-positive, HER2 IHC 0 mBC and an ESR1 mutation who has ultralow HER2 expression on rebiopsy of new liver lesions (1:12:35) Identification and Management of Adverse Events with T-DXd (1:20:27) Case: A woman in her late 40s with HR-positive, HER2 IHC 2+ mBC who experienced persistent low-grade nausea with T-DXd that resolved with olanzapine (1:34:02) Case: A woman in her early 60s with ER-positive, HER2 2+ mBC who received T-DXd resulting in fatigue and asymptomatic interstitial lung disease (1:48:58) CME information and select publications
Guest Kristy Red-Horse is a biologist who specializes in coronary artery development and disease. She says the latest advances in treatment of blockages could do away with invasive bypass surgeries in favor of growing new arteries using molecules like CXCL12, known to promote artery regrowth in mice. Red-Horse explains how leaps forward in medical imaging, expanding atlases of gene expressions, and new drug delivery mechanisms could someday lead to trials in humans. But, before that day can arrive, much work remains, as Red-Horse tells host Russ Altman in this episode of Stanford Engineering's The Future of Everything podcast.Have a question for Russ? Send it our way in writing or via voice memo, and it might be featured on an upcoming episode. Please introduce yourself, let us know where you're listening from, and share your quest. You can send questions to thefutureofeverything@stanford.edu.Episode Reference Links:Stanford Profile: Kristy Red-HorseKristy's Lab: Red-Horse LabConnect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>> Twitter/X / Instagram / LinkedIn / FacebookChapters:(00:00:00) IntroductionRuss Altman introduces Kristy Red-Horse, a professor of biology at Stanford University.(00:03:46) Replacing Open-Heart SurgeryWhy bypass surgery is invasive, risky, and requires long recovery.(00:05:09) Challenges in Artery GrowthThe difficulty of targeting artery growth with medical interventions.(00:07:32) The Role of Collateral ArteriesDefinition and function of collateral arteries as natural bypass.(00:09:37) Triggers for Natural Bypass FormationGenetic factors that may influence the growth of these bypass arteries.(00:10:49) Unique Properties of Coronary ArteriesChallenges of ensuring artificial growth replicates natural artery function.(00:13:04) The Discovery of CXCL12A key molecule that stimulates collateral artery formation.(00:16:16) Precise Artery Growth ControlThe results of targeted CXCL12 injections into mice hearts.(00:17:32) CXCL12's Overlooked RoleThe molecule's role in the immune system and stem cells.(00:20:27) Guinea Pigs and Heart Attack ResistanceHow guinea pigs naturally develop collaterals.(00:23:19) Preventing Heart DiseaseUsing artery growth treatments to target early-stage coronary disease.(00:25:25) Breakthroughs in Imaging TechnologyNew technology that enables identification of collateral growth pathways.(00:27:07) How Collateral Arteries FormThe two mechanisms in which new arteries form.(00:28:48) The Future of Medical Artery GrowthThe possibility of eliminating bypass surgery with targeted artery growth. Connect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>>Twitter/X / Instagram / LinkedIn / Facebook
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/XJJ865. CME/MOC/CE/AAPA/IPCE credit will be available until February 24, 2026.Fortifying the Framework for HER2+ GI Cancers: Precision Treatment Planning With Molecularly Targeted Therapies in GC/GEJC, CRC, and BTC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/XJJ865. CME/MOC/CE/AAPA/IPCE credit will be available until February 24, 2026.Fortifying the Framework for HER2+ GI Cancers: Precision Treatment Planning With Molecularly Targeted Therapies in GC/GEJC, CRC, and BTC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/XJJ865. CME/MOC/CE/AAPA/IPCE credit will be available until February 24, 2026.Fortifying the Framework for HER2+ GI Cancers: Precision Treatment Planning With Molecularly Targeted Therapies in GC/GEJC, CRC, and BTC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/XJJ865. CME/MOC/CE/AAPA/IPCE credit will be available until February 24, 2026.Fortifying the Framework for HER2+ GI Cancers: Precision Treatment Planning With Molecularly Targeted Therapies in GC/GEJC, CRC, and BTC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/XJJ865. CME/MOC/CE/AAPA/IPCE credit will be available until February 24, 2026.Fortifying the Framework for HER2+ GI Cancers: Precision Treatment Planning With Molecularly Targeted Therapies in GC/GEJC, CRC, and BTC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/XJJ865. CME/MOC/CE/AAPA/IPCE credit will be available until February 24, 2026.Fortifying the Framework for HER2+ GI Cancers: Precision Treatment Planning With Molecularly Targeted Therapies in GC/GEJC, CRC, and BTC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.Disclosure information is available at the beginning of the video presentation.
A free way to support your cancer treatment? Shifting your mindset and finding the positives in life. This week, I'm joined by Taylor Dukes, a family nurse practitioner, mother of two, and former colleague. We sat down to discuss her cancer journey—from finding out she had a brain tumor to entering remission—what she's learned in the years since her initial diagnosis, and how reframing her mindset helped her thrive. In this episode, you'll discover: Integrative Approaches to Cancer Treatment: When doctors found a brain tumor in Dukes' right frontal lobe, the mother of two didn't jump straight into surgery. Instead, she implemented a lot of integrative therapies such as coffee enemas, hyperbaric oxygen chamber therapy, wearing a red light helmet, and more. "In the five months between when I got diagnosed and when I actually had surgery, we were able to shrink the brain tumor in half," says Duke." The Power of Positive Thinking: Dukes, who currently has "no evidence of disease," believes that as long as you're breathing, there is always hope and there are always options. "No diagnosis, no test, no statistic has the ability to figure out the number of your days," says Dukes, who credits prayer and meditation for her mindset. "Your mind is powerful and what you believe is so, so powerful." Maintaining Your Health After Cancer: Two years after her diagnosis, Dukes is now in maintenance mode and focuses on getting her immune system back on track. She keeps up with regular fasting, eats a lower-carb diet, and alternates between red light therapy, ozone therapy, and sauna. “I'm starting specific therapies to target the co-infections and Lyme markers I have,” she says. 06:40 A Life-Changing Diagnosis 10:15 Integrative Approach to Healing 18:19 The Power of Faith and Family 20:26 Life After Surgery 24:41 Immune System Suppression and Cancer Growth 25:01 Prevention and Immune System Recovery 25:26 Targeted Therapies and Integrative Approaches 26:55 Conventional vs. Integrative Treatment Options 31:11 Support Systems and Personal Decisions 34:08 Navigating Parenthood During Cancer 37:55 Coping Mechanisms and Emotional Resilience Connect with Dr. Myers: Website: https://www.amymyersmd.com/ Newsletter: https://www.amymyersmd.com/ec/guide-to-leaky-gut Facebook: https://www.facebook.com/AmyMyersMD Instagram: https://www.instagram.com/amymyersmd/ Connect with Taylor Dukes: Website: https://taylordukeswellness.com/ Online store: https://shop.taylordukeswellness.com/collections/all-products Instagram: https://www.instagram.com/taylordukeswellness/ Facebook: https://www.facebook.com/taylordukeswellness/ Tik Tok: https://www.tiktok.com/@taylordukeswellness
Synopsis: Adverse reactions involving the skin, nails, and hair are common among patients undergoing treatment for cancer and are often underreported and overlooked. These reactions directly impact patient quality of life and may be the reason for interruptions in lifesaving antineoplastic treatment. To address these toxicities, the Association of Cancer Care Centers (ACCC) is leading an initiative that aims to educate providers and other cancer care team members about the optimal management of dermatologic side effects. In this episode, CANCER BUZZ speaks with Julie Ryan Wolf, PhD, MPH and C.J.G. (Corina) van den Hurk, PhD, the chair and vice chair of the Oncodermatology Study Group at the Multinational Association of Supportive Care in Cancer (MASCC) about common oncodermatological toxicities including radiation dermatitis, hair loss, and nail changes unique to EGFR-inhibitors. Also discussed are strategies to increase provider collaboration to intervene at an early stage to improve quality of life for patients receiving cancer treatment. “If we have symptom monitoring on a regular basis throughout the course of treatment, we'll be able to intervene sooner… helping improve [patient] quality of life” – Julie Ryan Wolf, PhD, MPH “In effect, almost each patient has a dermatologic side effect at the end of the treatment, or has experienced that during the treatment, and they are all very interfering.” – CJG (Corina) van den Hurk, PhD Julie Ryan Wolf, PhD, MPH Chair, Oncodermatology Study Group Multinational Association of Supportive Care in Cancer (MASCC) Associate Professor, Department of Dermatology, Department of Radiation Oncology University of Rochester Medical Center Rochester, NY CJG (Corina) van den Hurk, PhD Vice Chair, Oncodermatology Study Group Multinational Association of Supportive Care in Cancer (MASCC) Senior Researcher, Santeon Hospitals Netherlands Thank you to Johnson & Johnson for their support of this program. Additional Reading/Sources Multinational Association of Supportive Care in Cancer (MASCC) Home Multinational Association of Supportive Care in Cancer (MASCC) Oncodermatology Study Group MASCC Study Group Evidence-Based Clinical Practice Guidelines ACCC Supportive Care Strategies for Dermatologic Toxicities Related to Cancer Therapies Oncology Issues – Supportive Oncodermatology: Addressing dermatologic adverse events associated with oncologic therapies Dermatologic Adverse Events of Systemic Anticancer Therapies: Cytotoxic Chemotherapy, Targeted Therapy, and Immunotherapy Oncodermatology: Advancing the Science and Care of Cancer Patients and Survivors Supportive oncodermatology-a narrative review of its utility and the way forward =
Arun Krishna, Vice President and franchise head for an AstraZeneca US OBU, shares details of a treatment option with TAGRISSO® (osimertinib). AstraZeneca is focused on the development of new treatments, prioritizing researching options in eligible patients. Listen to the full podcast episode to learn more. Please see Important Safety Information for TAGRISSO. Please see complete Prescribing Information, including Patient Information for TAGRISSO.See omnystudio.com/listener for privacy information.
Guest Renee Zhao works at the cutting-edge of robotic surgery – literally. Emboldened by advances in 3D-printing and miniaturization, she builds “millibots,” magnet-controlled, millimeter-scale soft robots that navigate the bloodstream to remove blood clots and treat brain aneurysms. While the millibot's promise is clear, much work remains before the devices are commonplace. Revolutionizing health care with surgical robots will require a delicate balance of design, buildability, and functionality, Zhao tells host Russ Altman on this episode of Stanford Engineering's The Future of Everything podcast.Have a question for Russ? Send it our way in writing or via voice memo, and it might be featured on an upcoming episode. Please introduce yourself, let us know where you're listening from, and share your quest. You can send questions to thefutureofeverything@stanford.edu.Episode Reference Links:Stanford Profile: Renee ZhaoConnect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>> Twitter/X / Instagram / LinkedIn / FacebookChapters:(00:00:00) IntroductionRuss Altman introduces guest Renee Zhao, a professor of mechanical engineering at Stanford University.(00:03:34) Robotic Surgery and HealthcareRenee's inspiration for soft robotics and its potential in healthcare applications.(00:05:49) Current Status of Robotic SurgeryCurrent robotic surgery technologies and the push for more advanced solutions.(00:09:32) Nature-Inspired Soft RoboticsHow soft robotic systems are ideal for working within delicate human tissues.(00:11:41) Millirobotic SystemsRecently developed millimeter-sized robots that swim and navigate blood vessels.(00:14:46) Millirobot ControlThe role of magnetic fields and imaging technology for robot navigation.(00:17:18) Treating Blood Clots and AneurysmsThe multifunctional abilities of robots to deliver drugs and treat blood clots.(00:19:46) Doctor's Reaction to New TechnologyExcitement for the new robotic advancements amongst the need for better tools.(00:21:04) Trends in Robot Size and FunctionalityThe design challenges for creating small yet functional robots.(00:25:52) AI and Machine Learning in Robotic DesignAI's role in optimizing robot design for specific patients.(00:28:59) Why Millimeter-Scale RobotsWhy millirobots strike the right balance for performance and functionality.(00:32:34) Conclusion Connect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>>Twitter/X / Instagram / LinkedIn / Facebook
In this episode of Onc Now, Jonathan welcomes Ahmad Awada, Head of the Oncology Department at Chirec Cancer Institute in Brussels and Editor in Chief of EMJ Oncology. Together they discuss groundbreaking developments in cancer care, the promise of targeted therapies, and the importance of global collaboration in oncology. Timestamps: (00:00)-Introduction (01:20)-Reflecting on ESMO 2024 (07:37)-Looking ahead to ESMO 2025 (10:04)-Pharmacokinetics and Pharmacodynamics of Antibody-Drug Conjugates (13:24)-New cytotoxics and molecular targeted therapies for solid tumours (16:30)-Surgery of primary tumour in de novo metastatic breast cancer (19:29)-Improving survival in cancer patients (22:47)-Managing the risk of thromboembolism (24:43)-Exciting advancements on the horizon (29:38)-Wishes for oncology
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete EBAC/CME information, and to apply for credit, please visit us at PeerView.com/FQV865. EBAC/CME credit will be available until December 22, 2025.What's Around the Corner in Advanced Prostate Cancer? Candid Conversations to Future Proof Your Practice for Targeted Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.
This week we're joined by Eric Green, Founder and CEO of Trace Neuroscience, Co-Founder and Chief Scientific Officer at Maze Therapeutics, and Adjunct Clinical Assistant Professor at Stanford University School of Medicine. Eric and Patrick discuss Eric's transition from cardiology to the world of entrepreneurship, the role of highly focused biotechs in creating precision therapies, and the development of high-impact gene therapies for people with amyotrophic lateral sclerosis (ALS).
Featuring perspectives from Dr Suresh S Ramalingam and Dr Gregory J Riely, including the following topics: Introduction: Tumor Treating Fields (0:00) Nontargeted Therapy for Lung Cancer — Dr Ramalingam (4:02) Targeted Therapy for Non-Small Cell Lung Cancer — Dr Riely (33:50) CME information and select publications
© 2020-2025 Ivy Podcast Discovery LLC
